Home / Leadership / Dr. Patrick Smith
Dr. Patrick Smith Senior Vice President, Integrated Drug Development and Strategy

With over 20 years of global drug development experience, Patrick works across all phases of development with particular expertise in infectious diseases, oncology, and inflammation as well as novel early development program design and applying modeling and simulation to solve critical development problems. Patrick has over 125 peer reviewed publications, in journals including NEJM and Lancet.


Smith PF, Dodds M, Bentley D, Yeo K, Rayner C. Dosing will be a key success factor in repurposing antivirals for COVID-19Br J Clin Pharmacol. 2020;10.1111/bcp.14314.

Rayner CR, Smith PF, Hershberger K, Wesche D. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders. Clin Transl Sci. 2020;10.1111/cts.12790.

Gonçalves, A., Bertrand, J., Ke, R., Comets, E., de Lamballerie, X., Malvy, D., Pizzorno, A., Terrier, O., Rosa Calatrava, M., Mentré, F., Smith, P., Perelson, A. S., & Guedj, J. (2020). Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral loadCPT: pharmacometrics & systems pharmacology, 10.1002/psp4.12543. https://doi.org/10.1002/psp4.12543

Sloan, S. E., Szretter, K. J., Sundaresh, B., Narayan, K. M., Smith, P., Skurnik, D., Bedard, S., Trevejo, J. M., Oldach, D., & Shriver, Z. (2020). Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge studyAntiviral research, 104763. Advance online publication. https://doi.org/10.1016/j.antiviral.2020.104763

Patel, K., Kirkpatrick, C. M., Nieforth, K. A., Chanda, S., Zhang, Q., McClure, M., Fry, J., Symons, J. A., Blatt, L. M., Beigelman, L., DeVincenzo, J. P., Huntjens, D. R., & Smith, P. F. (2019). Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humansThe Journal of antimicrobial chemotherapy74(2), 442–452. https://doi.org/10.1093/jac/dky415

Kamal MA, Smith PF, Chaiyakunapruk N, Wu DBC, Pratoomsoot C, Lee KKC, Chong HY, Nelson RE, Nieforth K, Dall G, Toovey S, Kong DCM, Kamauu A, Kirkpatrick CM, Rayner CR.  Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.  Br J Clin Pharmacol. 2017 Jul;83(7):1580-1594.

AM Wollacott, MF Boni, KJ Szretter, SE Sloan, M Yousofshahi, K Viswanathan, S Bedard, CA Hay, PF Smith, Z Shriver, JM Trevejo.  Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A OutbreaksEBioMedicine 5 (2016), 147-155.

JP DeVincenzo, MW McClure, JA Symons, H Fathi, C Westland, S Chanda, R Lambkin-Williams, P Smith, Q Zhang,L Beigelman,LM. Blatt, J Fry.  Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge StudyNew England Journal of Medicine 11/2015; 373(21):2048-2058.

Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialLancet. 2010 Oct 30;376(9751):1467-75.

Back to top